Pharmaceutical - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

401 to 420 of 420 results

GlaxoSmithKline launches $50 million Life Sciences Innovation Fund in Canada

13-11-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) has launched the GSK Canada Life Sciences Innovation Fund,…

FinancialGlaxoSmithKlineNorth AmericaPharmaceuticalResearch

Systemic lupus erythematosus drug market to grow to $1.6 billion in 2018

10-11-2011

The global systemic lupus erythematosus (SLE) therapeutics market in the seven leading countries ( the…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineGlobalHuman Genome SciencesMarkets & MarketingPharmaceutical

Mylan to acquire Pfizer generic respiratory delivery platform; challenge to GSK

10-11-2011

US generic drug major Mylan (Nasdaq: MYL) has entered into an agreement with global pharma behemoth Pfizer…

Advair DiskusGenericsGlaxoSmithKlineLicensingMylan LaboratoriesPfizerPharmaceuticalRespiratory and PulmonarySeretide

GlaxoSmithKline finalizes $3 billion deal with US government over marketing practices

04-11-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday that it has reached an agreement in principle…

AvandiaFinancialGlaxoSmithKlineLegalNorth AmericaPharmaceutical

Hepatitis B vaccines market forecast to show moderate growth until 2018

03-11-2011

The global hepatitis B vaccines market is estimated to be worth $997.0 million in 2010, and is forecast…

Anti-viralsGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalVaccines

Important decision for the biotech industry from UK Supreme Court

03-11-2011

The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

GlaxoSmithKline posts solid 3rd-qtr results, in line with expectations; joins WIPO scheme

27-10-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) seems to have overcome some of its problems, such exceptional…

FinancialGlaxoSmithKlinePharmaceuticalResearch

Benlysta to drive lupus drug market to $2.1 billion in 2020

26-10-2011

Driven primarily by the launch and uptake of Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseases

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news

20-10-2011

UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports

18-10-2011

Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Epizyme earns $4 million pre-clinical milestone from GSK under novel HMT therapeutics alliance

17-10-2011

Privately-held US biotech startup Epizyme says it has achieved a pre-clinical milestones in its alliance…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncologyPharmaceutical

ViiV Healthcare announces 16 new grantees for 2011/2012 to prevent mother-to-child HIV transmission

13-10-2011

ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsFinancialGlaxoSmithKlineHealthcarePfizerPharmaceuticalRest of the WorldViiV Healthcare

In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions

04-10-2011

The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company…

Asia-PacificBoehringer IngelheimDiabetesEli LillyGlaxoSmithKlineMarkets & MarketingMergers & AcquisitionsPharmaceutical

Cost benefit analysis of cervical cancer vaccines sees Gardasil beat Cervarix

29-09-2011

An analysis of cervical-cancer vaccine has shown that Merck & Co’s (NYSE: MRK) Gardasil (human papillomavirus…

CervarixEuropeGardasilGlaxoSmithKlineMerck & CoPharmaceuticalPricingVaccines

Medicines Australia starts new Code of Conduct review

26-09-2011

Pharma trade group Medicines Australia has commenced a Review of its Code of Conduct and invites public…

Asia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalRegulation

ViiV Healthcare withdraws applications of once-daily Celsentri/Selzentry

21-09-2011

UK-based ViiV Healthcare, a global specialist HIV company established in November 2009 by UK pharma giant…

Anti-viralsCelsentriEuropeGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationSelzentryViiV Healthcare

Amgen’s Prolia increases bone mineral density over eight; new indications approved

20-09-2011

The world’s largest biotechnology firm, USA-based Amgen (Nasdaq: AMGN) says that new long-term data…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlinePharmaceuticalProliaRegulationResearchXgeva

401 to 420 of 420 results

Back to top